Asphalion experts Jordi Silvestre and Marta Morales participated in the 18-month follow-up meeting of Horizon 2020 project Tumor-LN-oC that has taken place in Athens this week. The meeting, which was attended by all partners with representatives from the fields of microfluidics, cell biology, cancer biology, physics, computer programming and regulatory affairs, was the third meeting of the Tumor-LN-oC consortium, allowing the participants to meet in person to review the last 6 months of progress.
Asphalion used this opportunity to present the results of the regulatory roadmap that is currently preparing for the project, as well as talking about the next steps of the ITF meeting that is planned to be conducted in the following months.
The EU-funded Tumor-LN-oC project proposes the development and validation of a TRL 5 tumor-lymph node-on-chip (Tumor-LN-oC) platform composed of 3D tissue models and microfluidic chips which will connect surgically removed human primary tumors and LN tissue from the same lung cancer patient. This will serve as a “biological twin” of the patient and will allow to study the interaction of primary tumors with LNs for individual patients.
For a complete overview about the project, we invite you to have a look at the website: TUMOR LN OC PROJECT WEBSITE
For additional information, you can also contact us at: info@asphalion.com
